Jubbonti (Denosumab)

Denosumab is a monoclonal antibody that inhibits bone resorption and is indicated for several bone‑related conditions.

• Postmenopausal osteoporosis: reduces fracture risk by increasing bone density.
• Osteoporosis in men at high risk of fracture: improves bone strength and lowers fracture incidence.
• Bone loss associated with glucocorticoid therapy: mitigates steroid‑induced bone deterioration.
• Prevention of skeletal‑related events in patients with bone metastases from solid tumours: delays progression of bone complications.
• Giant cell tumor of bone: limits tumour growth and recurrence.

• Denosumab binds with high affinity to the receptor activator of nuclear factor‑κB ligand (RANKL), preventing its interaction with the RANK receptor on osteoclast precursors. This inhibition blocks osteoclast formation, reduces their activity and promotes apoptosis, leading to decreased bone resorption and increased bone mass.

Denosumab may cause a range of adverse reactions, from mild injection‑site symptoms to serious systemic events.

Common Side Effects

• Injection site pain or erythema.
• Low blood calcium (hypocalcemia).
• Musculoskeletal pain.
• Upper respiratory tract infection.
• Skin rash.
• Nausea.

Serious or Rare Side Effects

• Osteonecrosis of the jaw.
• Atypical femur fracture.
• Severe hypersensitivity reactions, including anaphylaxis.
• Serious infections.
• New onset or worsening of autoimmune conditions.
• Unexplained severe bone pain.

Before using Denosumab, consider the following safety measures.

• Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
• Dental health: obtain a dental examination and complete any invasive procedures before starting therapy.
• Renal function: monitor patients with severe kidney impairment closely.
• Concomitant anti‑resorptive therapy: avoid simultaneous use with other bone‑targeting agents.
• Pregnancy and lactation: use only if clearly needed, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid)

• Concurrent use with other potent anti‑resorptives (e.g., bisphosphonates) may increase risk of severe hypocalcemia.
• High‑dose calcium supplements without monitoring can exacerbate hypercalcemia after discontinuation.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., methotrexate) may heighten infection risk.
• Hormone replacement therapy may alter calcium balance.
• Anticonvulsants that affect vitamin D metabolism may require calcium/vitamin D monitoring.
• Chronic corticosteroid therapy can amplify bone loss, necessitating closer observation.
• Live vaccines should be avoided during treatment due to potential reduced immune response.